Effect of CTLA4-Ig on severe asthma (ECSA) study ; Double blind, placebo controlled, phase IIa trial of CTLA4-Ig (abatacept) on severe asthma

Trial Profile

Effect of CTLA4-Ig on severe asthma (ECSA) study ; Double blind, placebo controlled, phase IIa trial of CTLA4-Ig (abatacept) on severe asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Abatacept (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ECSA
  • Most Recent Events

    • 22 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jul 2015 Planned End Date changed to 30 Apr 2016, according to University Hospital Medical Information Network - Japan record.
    • 05 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top